Nasdaq News
Americans Are Facing a $3.83 Trillion Retirement Shortfall. Here's What to Do About It
How Could Recent COVID-19 Vaccine News Impact Stocks Like Boeing or DocuSign?
3 Growth Stocks I'd Buy Right Now
SPACs Are in a Bubble, but These 3 Stocks Will Make It Through
The 1 Stock I'd Buy Right Now
Is Guardant Health Stock a Buy?
Is Canopy Growth Stock a Buy?
Dr. Reddy's, RDIF Get Approval To Conduct Clinical Trial For Sputnik V COVID 19 Vaccine In India
Why I Think Bristol Myers Squibb Is Too Cheap to Miss
The Best Pot Stock for the Next 10 Years
Quidel and OPKO Health Are Scoring With Coronavirus Testing in Sports. Is the Market Missing It?
Better Coronavirus Stock: AstraZeneca or Moderna?
GOL, American Airlines' Codeshare Pact to Boost Connectivity
The Weekly Wrap – Brexit, COVID-19, and U.S Politics Drive the Majors
Apple’s New iPhone Launch Bodes Well for Qualcomm; Top Analyst Says ‘Buy’
Apple’s hotly anticipated iPhone 12 launch hogged Tuesday’s technology headlines, but for Canaccord analyst Michael Walkley, the launch acts as confirmation of the bull thesis for chipmaker Qualcomm (QCOM).
With all four new models boasting 5G capabilities, it is Qualcomm, Walkley says, that stands to benefit from the new “long-term 5G investment cycle.”
“We anticipate strong earnings in F2021 and beyond as 5G smartphones ramp, the mix of 5G growth benefitting Qualcomm with 50% greater content than a 4G smartphone, Apple re-enters the model for QCT shipments, and Huawei returns to the model for licensing payments,” the 5-star analyst said.
Qualcomm has already signed off on long-term deals with all leading OEMs and its QTL (Qualcomm Technology Licensing) segment now boasts over 100 5G licenses.
Walkley believes the mix of steadily improving smartphone sales and the 5G opportunity should “lead to sustained growth through F2022.” The analyst estimates “the mix of 5G smartphones will grow from roughly 200M units in C2020 to 450M-500M units in C2021 to roughly 1B units in C2022.”
In fact, together with strong growth opportunities in markets such as IoT and automotive, Walkley anticipates QCT (Qualcomm CDMA Technologies) will grow its revenue from $16.10 billion in F2020 to $24.2 billion in F2022.
Moreover, at Apple’s launch event, Verizon’s CEO joined the presentation to announce its goal of bringing 5G Ultra-Wideband services to 60 cities this year. For Walkley, Verizon’s ambition further adds to the Qualcomm bull case.
“We view the concurrent iPhone launch and Verizon announcement as a strong positive for 5G customer adoption as 5G service expands across the globe at a greater scale. With 5G sales ramping and Qualcomm’s leadership position, we believe this should drive strong earnings growth,” Walkley summed up.
All in all, Walkley reiterated a Buy on QCOM shares, alongside a $150 price target. What’s in it for investors? Upside of 16% from current levels. (To watch Walkley’s track record, click here)
The Street currently has a cautiously optimistic outlook for the chip giant. The analyst consensus rates Qualcomm a Moderate Buy based on 15 Buys vs. 8 Holds. However, shares have had a bountiful 2020 and are up by 44% year-to-date, and as such, the $128.33 average price target suggests they will stay range bound for the foreseeable future. (See QCOM stock analysis on TipRanks)
To find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.
Disclaimer: The opinions expressed in this article are solely those of the featured analyst. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.
Vaxart: An Alternative Opportunity in the COVID-19 Vaccine Landscape
On Tuesday, vaccine specialist Vaxart (VXRT) announced it has dosed the first subject in the Phase 1 study of VXA-CoV2-1, the company’s oral, room-temperature stable COVID-19 vaccine candidate.
After the vaccine impressed in preclinical models, it is a timely announcement from Vaxart. While the small biotech is significantly behind other, mostly bigger competitors in its Covid-19 vaccine program, as recent events have shown, bringing to market a viable solution is far from hassle free.
Earlier this week, Johnson & Johnson halted its Covid-19 vaccine candidate’s Phase 3 study due to a participant’s unexplained illness. That event was swiftly followed by Eli Lily pausing enrollment for its Covid-19 treatment program due to safety concerns.
For FBR Riley analyst Mayank Mamtani, the bigger players’ struggles highlight the alternative opportunity Vaxart presents for investors.
“As the COVID-19 cases continue to spike WW and leading programs from J&J and AZN experience speedbumps with late-stage development, albeit temporary, it is becoming increasingly important to have multiple shots on goal in the C-19 vaccine landscape and recommend investors diversify positions, including with alternative modalities, e.g., VXRT’s oral candidate, which not only have the potential to be self-administered but are also room-temperature stable and rapidly scalable, conferring significant advantages with respect to stockpiling and distribution, particularly relevant in non-western economies with limited healthcare resources,“ Mamtani commented.
Vaxart stock has experienced a roller coaster ride in 2020. Despite being up by 1637% year-to-date, the share price has actually retreated by over 60% since the July yearly highs. Mamtani believes that in addition to the pullback, its “valuation disconnect relative to more advanced C-19 vaccine peers, presents an additional compelling buying opportunity.”
To this end, Mamtani rates VXRT a Buy along with a $22 price target. Investors could be pocketing a massive 262% gain, should his thesis play out over the next year. (To watch Mamtani’s track record, click here)
Overall, only one other analyst is currently keeping a tab on Vaxart’s progress, also recommending the stock a Buy. Vaxart, therefore, has a Moderate Buy consensus rating backed with a $19.50 average price target. The figure suggests potential upside of 220% in the year ahead. (See VXRT stock analysis on TipRanks)
To find good ideas for healthcare stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.
Disclaimer: The opinions expressed in this article are solely those of the featured analyst. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.